SCHEMBL2071431

SCHEMBL2071431

COC(=O)c1n[nH]c2cccc(Cl)c2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.55
▸ STAT3 P40763 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ NR4A2 P43354 2/20 0.51
▸ GAA P10253 1/20 0.45
▸ MAP2K4 P45985 4/20 0.44
▸ TTK P33981 2/20 0.42
▸ EPHB3 P54753 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ FLT3 P36888 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ PBRM1 Q86U86 1/20 0.39
▸ F2 P00734 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791540 0.90 KDM4E (0.59) KDM4ESTAT3HIF1ANR4A2GAA
SCHEMBL25206400 0.83 KDM4E (0.55) KDM4ESTAT3HIF1ANR4A2FLT3
SCHEMBL8638951 0.82 GAA (0.50) GAAMAP2K4TTKEPHB3CHEK1
SCHEMBL2072624 0.80 KDM4E (0.45) KDM4EGAAMAP2K4LMNAHSD17B10
SCHEMBL7374273 0.77 GAA (0.54) GAAMAP2K4TTKEPHB3PBRM1
SCHEMBL2599805 0.77 KDM4E (0.60) KDM4ESTAT3HIF1ANR4A2FLT3
SCHEMBL14271999 0.75 KDM4E (0.59) KDM4ESTAT3HIF1ANR4A2GAA
SCHEMBL7737920 0.75 KDM4E (0.59) KDM4ESTAT3HIF1AFLT3LRRK2
SCHEMBL2862825 0.75 KDM4E (0.59) KDM4ESTAT3HIF1ANR4A2MAP2K4
SCHEMBL28503864 0.74 KDM4E (0.57) KDM4ESTAT3HIF1ANR4A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 — — EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 — — US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R KDM4E 3537/4885STAT3 1795/4885HIF1A 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback